• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向小肠受体治疗便秘和腹泻。

Targeting Small Bowel Receptors to Treat Constipation and Diarrhea.

作者信息

John Elizabeth S, Chokhavatia Sita

机构信息

Department of Internal Medicine, Rutgers Robert Wood Johnson Medical School, 1 RWJ Place, New Brunswick, NJ, 08901, USA.

Valley Medical Group, Ridgewood, NJ, USA.

出版信息

Curr Gastroenterol Rep. 2017 Jul;19(7):31. doi: 10.1007/s11894-017-0573-x.

DOI:10.1007/s11894-017-0573-x
PMID:28593453
Abstract

BACKGROUND

The options for the treatment of diarrhea and constipation are evolving as emerging therapies target small bowel receptors. The goal of this review is to discuss small bowel receptors involved in intestinal absorption, secretion, and motility. The review highlights therapies already approved or currently being studied for the modulation of these receptors.

METHODS

The articles cited in this review focus on the molecular level of pathways involved in diarrhea and constipation, and highlight the respective pharmacotherapies.

RESULTS

The majority of the studies in the current literature investigate the effects of both the small and large intestine receptors on diarrhea and constipation. There are fewer studies that isolate the effects of these receptors solely on the small bowel, and focusing more on the receptors found distinctly in the small intestine may be an area of interest for future studies as this can inspire more targeted therapies.

摘要

背景

随着新兴疗法针对小肠受体,腹泻和便秘的治疗选择不断演变。本综述的目的是讨论参与肠道吸收、分泌和运动的小肠受体。该综述重点介绍了已获批或正在研究的用于调节这些受体的疗法。

方法

本综述引用的文章聚焦于腹泻和便秘所涉及途径的分子水平,并重点介绍了相应的药物治疗方法。

结果

当前文献中的大多数研究调查了小肠和大肠受体对腹泻和便秘的影响。单独研究这些受体对小肠的影响的研究较少,更多地关注小肠中特有的受体可能是未来研究的一个感兴趣领域,因为这可以激发更有针对性的疗法。

相似文献

1
Targeting Small Bowel Receptors to Treat Constipation and Diarrhea.靶向小肠受体治疗便秘和腹泻。
Curr Gastroenterol Rep. 2017 Jul;19(7):31. doi: 10.1007/s11894-017-0573-x.
2
Lubiprostone Accelerates Intestinal Transit and Alleviates Small Intestinal Bacterial Overgrowth in Patients With Chronic Constipation.鲁比前列酮可加速慢性便秘患者的肠道转运并减轻小肠细菌过度生长。
Am J Med Sci. 2016 Sep;352(3):231-8. doi: 10.1016/j.amjms.2016.05.012. Epub 2016 May 24.
3
Existing and emerging therapies for managing constipation and diarrhea.用于治疗便秘和腹泻的现有和新兴疗法。
Curr Opin Pharmacol. 2017 Dec;37:158-166. doi: 10.1016/j.coph.2017.10.015. Epub 2017 Nov 21.
4
Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.便秘型肠易激综合征和慢性特发性便秘的现有及新出现的治疗方法:聚焦于促分泌剂。
Pharmacotherapy. 2015 Jun;35(6):613-30. doi: 10.1002/phar.1594. Epub 2015 May 27.
5
The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.新型促动力和促分泌剂在慢性特发性便秘和便秘型肠易激综合征治疗中的应用。
Adv Ther. 2009 May;26(5):519-30. doi: 10.1007/s12325-009-0027-4. Epub 2009 May 14.
6
Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.神经胃肠病学的新兴疗法:埃卢多啉——腹泻型肠易激综合征的一种新治疗选择。
Neurogastroenterol Motil. 2016 Jan;28(1):26-35. doi: 10.1111/nmo.12716.
7
Carbon-based compounds emerging as sparkling diamonds for IBS treatment?碳基化合物会成为治疗肠易激综合征的璀璨“钻石”吗?
Aliment Pharmacol Ther. 2012 Jan;35(1):199-200; author reply 200-2. doi: 10.1111/j.1365-2036.2011.04893.x.
8
Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.用于治疗腹泻型肠易激综合征的埃卢多啉
Expert Opin Pharmacother. 2016 Jul;17(10):1395-402. doi: 10.1080/14656566.2016.1182982. Epub 2016 Jun 8.
9
Evaluating the functional net value of pharmacologic agents in treating irritable bowel syndrome.评估药物治疗肠易激综合征的功能净效值。
Aliment Pharmacol Ther. 2014 May;39(9):973-83. doi: 10.1111/apt.12692. Epub 2014 Mar 11.
10
Does the oral adsorbent AST-120 really improve symptoms for non-constipating irritable bowel syndrome?口服吸附剂AST-120真的能改善非便秘型肠易激综合征的症状吗?
Aliment Pharmacol Ther. 2012 Jan;35(1):197-8; author reply 198-9. doi: 10.1111/j.1365-2036.2011.04884.x.

引用本文的文献

1
TMAO is involved in kidney-yang deficiency syndrome diarrhea by mediating the "gut-kidney axis".氧化三甲胺通过介导“肠-肾轴”参与肾阳虚证腹泻的发生。
Heliyon. 2024 Jul 30;10(15):e35461. doi: 10.1016/j.heliyon.2024.e35461. eCollection 2024 Aug 15.
2
Action Mode of Gut Motility, Fluid and Electrolyte Transport in Chronic Constipation.慢性便秘中肠道运动、液体及电解质转运的作用模式
Front Pharmacol. 2021 Jul 27;12:630249. doi: 10.3389/fphar.2021.630249. eCollection 2021.
3
Paracellular Filtration Secretion Driven by Mechanical Force Contributes to Small Intestinal Fluid Dynamics.

本文引用的文献

1
A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation.一项关于尿鸟苷素类似物普卡那肽治疗慢性特发性便秘患者的随机 III 期临床试验。
Am J Gastroenterol. 2017 Apr;112(4):613-621. doi: 10.1038/ajg.2016.611. Epub 2017 Feb 7.
2
Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report.优化利那洛肽在便秘型肠易激综合征患者中的应用:专家共识报告
Adv Ther. 2017 Mar;34(3):587-598. doi: 10.1007/s12325-016-0473-8. Epub 2017 Jan 12.
3
A Comprehensive Comparison of the Efficacy and Tolerability of Racecadotril with Other Treatments of Acute Diarrhea in Adults.
机械力驱动的细胞旁滤过分泌有助于小肠液体动力学。
Med Sci (Basel). 2021 Feb 9;9(1):9. doi: 10.3390/medsci9010009.
消旋卡多曲与其他成人急性腹泻治疗方法的疗效和耐受性综合比较
Front Med (Lausanne). 2016 Oct 14;3:44. doi: 10.3389/fmed.2016.00044. eCollection 2016.
4
Lubiprostone Accelerates Intestinal Transit and Alleviates Small Intestinal Bacterial Overgrowth in Patients With Chronic Constipation.鲁比前列酮可加速慢性便秘患者的肠道转运并减轻小肠细菌过度生长。
Am J Med Sci. 2016 Sep;352(3):231-8. doi: 10.1016/j.amjms.2016.05.012. Epub 2016 May 24.
5
The role of naloxegol in the management of opioid-induced bowel dysfunction.纳洛西戈在阿片类药物引起的肠道功能障碍管理中的作用。
Therap Adv Gastroenterol. 2016 Sep;9(5):736-46. doi: 10.1177/1756283X16648869. Epub 2016 May 26.
6
Chronic Diarrhea: Diagnosis and Management.慢性腹泻:诊断与管理。
Clin Gastroenterol Hepatol. 2017 Feb;15(2):182-193.e3. doi: 10.1016/j.cgh.2016.07.028. Epub 2016 Aug 2.
7
Neuroimmunomodulation in the Gut: Focus on Inflammatory Bowel Disease.肠道中的神经免疫调节:聚焦炎症性肠病
Mediators Inflamm. 2016;2016:1363818. doi: 10.1155/2016/1363818. Epub 2016 Jul 4.
8
Lanreotide Autogel in the Treatment of Idiopathic Refractory Diarrhea: Results of an Exploratory, Controlled, Before and After, Open-label, Multicenter, Prospective Clinical Trial.兰瑞肽长效凝胶治疗特发性难治性腹泻:一项探索性、对照、前后对照、开放标签、多中心、前瞻性临床试验的结果。
Clin Ther. 2016 Aug;38(8):1902-1911.e2. doi: 10.1016/j.clinthera.2016.06.012. Epub 2016 Aug 8.
9
Modern Management of Irritable Bowel Syndrome: More Than Motility.肠易激综合征的现代管理:不止于动力。
Dig Dis. 2016;34(5):566-73. doi: 10.1159/000445265. Epub 2016 Jun 22.
10
What about clonidine for diarrhoea? A systematic review and meta-analysis of its effect in humans.可乐定治疗腹泻如何?对其在人体中的作用进行的系统评价和荟萃分析。
Therap Adv Gastroenterol. 2016 May;9(3):282-301. doi: 10.1177/1756283X15625586. Epub 2016 Jan 25.